Press "Enter" to skip to content

Moderna Boasts Of New Effective 2-In-1 Covid And Flu Vaccine In Time For Fall, But Who’s Actually Going To Get It

by Jacob M. Thompson


Earlier this month, biotech giant Moderna, made into a household name for the mRNA Covid-19 vaccines, announced promising phase 3 data for their influenza and Covid-19 combo vaccine.

According to a press release posted on June 10th:

Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.

“Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Moderna is the only company with a positive Phase 3 flu and COVID combination vaccine. Building on the momentum of positive Phase 3 data across our respiratory portfolio, we continue to address significant unmet medical needs and advance public health.”

MRNA-1083 comprises components of mRNA-1010, Moderna’s vaccine candidate for seasonal influenza, and mRNA-1283, Moderna’s next-generation COVID-19 vaccine candidate. Each investigational vaccine has independently demonstrated positive Phase 3 clinical trial results.

Moderna plans to present the Phase 3 clinical data for mRNA-1083 at an upcoming medical conference as well as submit it for publication. The Company will engage with regulators on next steps…


Live Stream + Chat (


Home | Caravan to Midnight (

We Need Your Help To Keep Caravan To Midnight Going,

Please Consider Donating To Help Keep Independent Media Independent

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Breaking News: